WuXi PharmaTech (WX)
WuXi PharmaTech Retained Earnings Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
WX Retained Earnings Growth Range, Past 5 Years
| Minimum | 365.1% | Dec 2011 |
| Maximum | 1526% | Sep 2011 |
| Average | 945.5% |
About Retained Earnings Growth
Retained Earnings Growth is the percent increase/decrease of a company's retained net income over time. A company can use retained earnings to maintain current operations, or to invest in new ventures. Generally speaking, retained earnings growth is accompanied by subsequent increases in sales and profitability.
If a company's retained earnings at the end of 2008 were $12 million, and by the end of 2009 the company's retained earnings increased to $15 million, the company experienced a retained earnings growth of 25%.
Learn More
You may also be interested in these WX related companies
WX News
From Earlier: WuXi PharmaTech Receives GLP Statement for Suzhou Toxicology Facility
May 31, 7:42AM Benzinga
May 31, 7:42AM Benzinga
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Profit Margin
May 23, 2:27AM Benzinga
May 23, 2:27AM Benzinga
Interviews with Julian Robertson & Jim Chanos: Columbia Business School Newsletter http://stks.co/3luq $GOOG $AAPL $WX $AVP $IR $LM $HRB
about 23 days ago by marketfolly
about 23 days ago by marketfolly
$WX http://stks.co/2vE7 Setting up for C&H fans. Nice rounded bottom.
about 76 days ago by Fibline
about 76 days ago by Fibline
$WX http://stks.co/2rTh Too V ish for me to buy here but this is a nice chart if rests a bit.
about 80 days ago by szaman
about 80 days ago by szaman
Jefferies Reiterates a 'Buy' on WuXi PharmaTech (WX); Demand As Good As Ever
Mar 12, 11:28AM Street Insider
Mar 12, 11:28AM Street Insider
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2011 Results, Share Repurchase Program
Mar 08, 4:30PM PR Newswire
Mar 08, 4:30PM PR Newswire
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Revenue
Mar 02, 2:59AM Benzinga
Mar 02, 2:59AM Benzinga
WuXi PharmaTech Announces Purchase of Ordinary Shares from General Atlantic
Feb 15, 4:00AM PR Newswire
Feb 15, 4:00AM PR Newswire
$WX 200 Day SMA Cross - Price crossed above 200 day SMA (14.1363). Confirmed by volume.
about 121 days ago by TradeIdeasQuant
about 121 days ago by TradeIdeasQuant
WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
Jan 09, 9:00AM PR Newswire
Jan 09, 9:00AM PR Newswire
Jefferies Cuts Price Targets on WuXi PharmaTech (WX), Outlook Remains Strong Following Acquisitions
Nov 14, 9:30AM Street Insider
Nov 14, 9:30AM Street Insider
WuXi PharmaTech sees growth in FY11 revenues of China-based lab services 14%-15%
Nov 10, 4:42PM FlyOnTheWall
Nov 10, 4:42PM FlyOnTheWall
$WX Reports Q3 EPS $0.27 vs $0.25 Est; Revenues $104M vs $102.21M Est
about 205 days ago by Benzinga
about 205 days ago by Benzinga
Coming up at 12:02 it's @tickerville Mid-Day view talking $LAD $WIRE $CSR $WX $AMD $AUY and more on http://stocktwits.tv
about 393 days ago by StockTwitsTV
about 393 days ago by StockTwitsTV
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| WX | 14.85 | +0.13 | +0.88% | 1.065B |
| WWWW | 15.27 | -0.65 | -4.08% | 740.60M |
| WWW | 41.01 | -1.50 | -3.53% | 1.996B |
| WWVY | 13.16 | -0.04 | -0.30% | 75.80M |
| WWIN | 3.71 | +0.01 | +0.27% | 90.41M |
| WWE | 7.64 | -0.24 | -3.05% | 569.03M |
| WST | 47.39 | -0.41 | -0.86% | 1.601B |
| WSR | 12.58 | -0.22 | -1.72% | 127.81M |
| WSM | 34.15 | -0.76 | -2.18% | 3.401B |
| WSH | 34.74 | -0.53 | -1.50% | 6.047B |
